Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

G. Basaran,Umut Demirci,Fatih Yildiz,Irfan Cicin,Burak Yasin Aktaş,Banu Ozturk,Sema Sezgin Goksu,Hasan Senol Coskun,Basak Oyan,Ozlem Sonmez,Yesim Eralp,Erhan Gokmen,Seyda Gunduz,Taner Korkmaz,Mehmet Ali Nahit Sendur,Serkan Keskin

Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

2020

G. Basaran
Umut Demirci
Fatih Yildiz
Irfan Cicin
Burak Yasin Aktaş
Banu Ozturk
Sema Sezgin Goksu
Hasan Senol Coskun
Basak Oyan
Ozlem Sonmez
Yesim Eralp
Erhan Gokmen
Seyda Gunduz
Taner Korkmaz
Mehmet Ali Nahit Sendur
Serkan Keskin

e13055Background: The combination of ribociclib with ET significantly increased progression free survival (PFS) and OS compared with ET in first line treatment of HR positive HER2 negative MBC. We ...

Keywords:

Metastatic breast cancer
Oncology
in patient
first line therapy
Letrozole
Pathology
Internal medicine
Medicine
Ribociclib
retrospective analysis
Hormone receptor
Progression-free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations